TAG ARCHIVES FOR justice

9
Feb2021

PRIM&R’s Diversity Advisory Group and Resources

Tags:
9 Feb
No comments

PRIM&R's Diversity Advisory Group (DAG) works to advance PRIM&R's goal of promoting a diverse and inclusive environment. It advises PRIM&R staff on strategies for fostering a membership community where differences can flourish and works to raise the profile of diversity as an issue that matters to the broader research oversight field. One way that PRIM&R is committed to acting against racism is by sharing information, and the DAG encourages members of the PRIM&R community to support the expansion of resources by contributing suggestions. Read more

19
Jan2021

Justice in Research: Reflections on the lessons of 2020

Tags:
19 Jan
Comments: 1

Last year, Heather H. Pierce, JD, MPH and I shared some thoughts about the Belmont Report at 40, and about the evolution and flexibility of the Belmont principles of respect for persons, beneficence, and justice in the face of changing circumstances. As we leave behind the extraordinary year of 2020, I have been thinking about how the pandemic, together with the Black Lives Matter social justice movement, has shone new, and I would say welcome, light on the principle of justice in research. Read more

18
Feb2020

Research Ethics Roundup: unkind science, data sharing standards, diversity in psychological research, and more

Tags:
18 Feb
Comments: 1

This edition of Research Ethics Roundup covers “unkind science” and the public’s waning trust, international efforts to develop data sharing standards, lack of diversity in psychological research subjects, and digital phenotyping.  Read more

30
Jul2019

PRIM&R’s Response to FDA’s Draft Guidance on Enhancing the Diversity of Clinical Trial Populations

Tags:
30 Jul
No comments

In June, the FDA issued a draft guidance, "Enhancing the Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs." The issuance of this guidance satisfies a mandate of the FDA Reauthorization Act of 2017 (FDARA), and builds on other recent efforts by the FDA to broaden eligibility criteria for clinical trials and avoid unnecessary exclusions. PRIM&R submitted comments on the guidance this week, and we wanted to share them with you and encourage you to consider submitting your own comments on this important topic—the FDA is accepting comments until August 6. Read more